Modern biotech has the tools to edit genes and design drugs, yet thousands of rare diseases remain untreated. According to executives from Insilico Medicine and GenEditBio, the missing ingredient for years has been finding enough smart people to continue the work. AI, they say, is becoming the force multiplier that …
This breakdown shows exactly how the Logic Quality and Community Trust scores were calculated, providing full transparency into our evaluation process.